SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K/A - Current report: [Amend]
SEC Accession No. 0001493152-23-016635
Filing Date
2023-05-12
Accepted
2023-05-12 16:10:31
Documents
12
Period of Report
2023-03-15
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-ka.htm   iXBRL 8-K/A 49927
  Complete submission text file 0001493152-23-016635.txt   223255

Data Files

Seq Description Document Type Size
2 XBRL SCHEMA FILE vodg-20230315.xsd EX-101.SCH 3245
3 XBRL LABEL FILE vodg-20230315_lab.xml EX-101.LAB 34240
4 XBRL PRESENTATION FILE vodg-20230315_pre.xml EX-101.PRE 22371
6 EXTRACTED XBRL INSTANCE DOCUMENT form8-ka_htm.xml XML 3408
Mailing Address 4621 TECHNOLOGY DRIVE GOLDEN CO 80403
Business Address 4621 TECHNOLOGY DRIVE GOLDEN CO 80403 (720) 859-4120
Vitro Biopharma, Inc. (Filer) CIK: 0000793171 (see all company filings)

IRS No.: 841012042 | State of Incorp.: NV | Fiscal Year End: 1031
Type: 8-K/A | Act: 34 | File No.: 000-17378 | Film No.: 23915756
SIC: 2836 Biological Products, (No Diagnostic Substances)